<DOC>
	<DOC>NCT00737633</DOC>
	<brief_summary>This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an extended period of time. All subjects eligible to enroll into this study will receive study drug.</brief_summary>
	<brief_title>Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults</brief_title>
	<detailed_description />
	<criteria>Have completed the qualifying DM230 trial If females of childbearing potential, subjects must be using adequate contraception Provide written informed consent Be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures Be greater than 80% compliant in study medication use during the last three visits for DM230 Subjects who have developed one or more morbidities during the DM230 trial that would pose a safety concern</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Glycemic Control</keyword>
</DOC>